Stockholm Myocardial Infarction with Nonobstructive Coronaries Study 3
NCT ID: NCT05426408
Last Updated: 2025-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
85 participants
INTERVENTIONAL
2022-11-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac MRI Prior to Invasive Coronary Angiography in Patients With Suspected Non-ST-Elevation Myocardial Infarction
NCT06566625
Prognostic Significance of CMR-Confirmed Infarct in MINOCA Patients from Sweden and Australia
NCT06889428
Study Comparing Two Administration Pathways for Adenosine During Microvascular Function Assessment
NCT06269874
Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2 Study on Diagnosis Made by Cardiac MRI
NCT02318498
Etiologic Mechanisms, Myocardial Changes and Prognosis of Patients With MINOCA
NCT04538924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with MINOCA undergoing CMR
Patients will be their own controls
Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Myocardial perfusion mapping will be investigated after administration of adenosine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Myocardial perfusion mapping will be investigated after administration of adenosine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 35-80 years
* reading and writing proficiency in Swedish
Exclusion Criteria
* Arrythmia and/or pacemaker (atrial fibrillation and AV-block I- III)
* Asthma or severe chronic obstructive lung disease
* eGFR \< 30 ml/min
* spontaneous coronary artery dissection
* acute pulmonary embolism
* acute myocardial infarction type 2
* cardiomyopathy other than takotsubo syndrome
* a previous myocardial infarction due to CAD
35 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Stockholm
OTHER_GOV
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Per Tornvall
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Per Tornvall, MD
Role: PRINCIPAL_INVESTIGATOR
Karolinska Instítutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Per Tornvall
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMINC-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.